GTN
MCID: GST010
MIFTS: 53

Gestational Trophoblastic Neoplasm (GTN)

Categories: Cancer diseases, Rare diseases, Reproductive diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Gestational Trophoblastic Neoplasm

MalaCards integrated aliases for Gestational Trophoblastic Neoplasm:

Name: Gestational Trophoblastic Neoplasm 11 19 58 14
Hydatidiform Mole 11 43 14 71
Molar Pregnancy 11 5 33
Gestational Trophoblastic Neoplasia 11 5
Gestational Trophoblastic Disease 43 71
Gestational Trophoblastic Tumor 19 53
Gtn 19 58
Gestational Trophoblastic Neoplasms 71
Hydatidiform Mole, Recurrent, 1 71
Trophoblastic Disease Nos 33
Hydatidiform Mole Benign 33
Trophoblastic Disorder 33
Trophoblastic Disease 33
Hydatidiform Mole Nos 33
Vesicular Mole Nos 33
Vesicular Mole 33

Characteristics:


Age Of Onset:

Adult 58

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 11 DOID:3590
ICD9CM 34 630
SNOMED-CT 68 156085008 417475006
ICD10 31 O01
MESH via Orphanet 44 D031901
UMLS via Orphanet 72 C1135868
Orphanet 58 ORPHA59305
UMLS 71 C0020217 C0278796 C1135868 more

Summaries for Gestational Trophoblastic Neoplasm

GARD: 19 Gestational trophoblastic tumors (GTT) are malignant forms of gestational trophoblastic disease. The tumor always follows pregnancy, most often molar pregnancy (hydatidiform mole; see this term). Four histological subtypes have been described: invasive mole, gestational choriocarcinoma, placental site trophoblastic tumor and epithelioid trophoblastic tumor (see these terms).

MalaCards based summary: Gestational Trophoblastic Neoplasm, also known as hydatidiform mole, is related to partial hydatidiform mole and gestational choriocarcinoma. An important gene associated with Gestational Trophoblastic Neoplasm is NLRP7 (NLR Family Pyrin Domain Containing 7), and among its related pathways/superpathways are Peptide hormone metabolism and Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors. The drugs Amifostine and Levoleucovorin have been mentioned in the context of this disorder. Affiliated tissues include placenta, lung and t cells, and related phenotypes are endocrine/exocrine gland and reproductive system

Orphanet: 58 A rare, malignant group of gestational trophoblastic diseases always following pregnancy, most often molar pregnancy (hydatidiform mole). Four histological forms are described: invasive mole, gestational choriocarcinoma, placental site trophoblastic tumor (PSTT) and epithelioid trophoblastic tumor (ETT).

Related Diseases for Gestational Trophoblastic Neoplasm

Diseases related to Gestational Trophoblastic Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 347)
# Related Disease Score Top Affiliating Genes
1 partial hydatidiform mole 33.1 NLRP7 KHDC3L
2 gestational choriocarcinoma 32.5 NLRP7 H19 CSH2 CSH1
3 placental site trophoblastic tumor 32.5 NLRP7 KHDC3L INHA CSH2 CSH1 CGB5
4 triploidy 32.1 NLRP7 KHDC3L
5 pre-eclampsia 31.6 INHA H19 CSH2 CSH1 CGB3 CGA
6 corpus luteum cyst 31.1 CSH2 CSH1 CGB5
7 down syndrome 31.0 INHA CGB5 CGB3 CGA
8 epithelioid trophoblastic tumor 30.8 NLRP7 KHDC3L CSH2 CSH1
9 hydatidiform mole, recurrent, 1 30.7 NLRP7 NCR1 MEI1 KHDC3L INHA H19
10 beckwith-wiedemann syndrome 30.6 NLRP7 NLRP5 KHDC3L HYMAI H19 CDKN1C
11 trophoblastic neoplasm 30.5 NLRP7 NLRP5 MIR517A MIR371A MEI1 KHDC3L
12 choriocarcinoma of ovary 30.4 CSH2 CSH1
13 choriocarcinoma 30.4 INHA H19 CSH2 CSH1 CGB5 CGB3
14 testicular cancer 30.4 MIR371A CGB5 CGB3 CGA
15 teratoma 30.4 MIR371A H19 CGB5 CGB3 CGA
16 ectopic pregnancy 30.2 MIR517A MIR371A CSH2 CSH1 CGB5 CGB3
17 non-gestational choriocarcinoma 30.2 CSH2 CSH1
18 placental abruption 30.1 MIR517A CGB5 CGB3 CGA
19 mixed germ cell cancer 30.1 CSH2 CSH1
20 silver-russell syndrome 1 30.1 NLRP7 NLRP5 KHDC3L H19 CDKN1C
21 adrenal cortical carcinoma 30.1 TERT INHA H19 CDKN1C
22 recurrent hydatidiform mole 11.9
23 hydatidiform mole, recurrent, 2 11.9
24 hydatidiform mole, recurrent, 3 11.8
25 hydatidiform mole, recurrent, 4 11.8
26 graves disease 1 10.9
27 hyperthyroidism 10.8
28 eclampsia 10.8
29 neutropenia 10.7
30 severe pre-eclampsia 10.6
31 amenorrhea 10.6
32 thyroid crisis 10.4
33 parkinson disease, late-onset 10.4
34 hypothyroidism, congenital, nongoitrous, 2 10.4
35 hypothyroidism, congenital, nongoitrous, 1 10.4
36 hypothyroidism, congenital, nongoitrous, 3 10.4
37 anencephaly 10.4
38 pemphigoid gestationis 10.4
39 ovarian hyperstimulation syndrome 10.4
40 testicular trophoblastic tumor 10.4 CSH2 CSH1
41 hemihyperplasia, isolated 10.3 H19 CDKN1C
42 patellofemoral pain syndrome 10.3 CGB3 CGA
43 non-gestational ovarian choriocarcinoma 10.3 CSH2 CSH1
44 gestational ovarian choriocarcinoma 10.3 CSH2 CSH1
45 deficiency anemia 10.3
46 rh isoimmunization 10.3 CSH2 CSH1
47 migraine with or without aura 1 10.3
48 umbilical hernia 10.3 HYMAI H19 CDKN1C
49 gynecomastia 10.3 INHA CGB5 CGA
50 childhood germ cell cancer 10.3 MIR371A H19

Graphical network of the top 20 diseases related to Gestational Trophoblastic Neoplasm:



Diseases related to Gestational Trophoblastic Neoplasm

Symptoms & Phenotypes for Gestational Trophoblastic Neoplasm

MGI Mouse Phenotypes related to Gestational Trophoblastic Neoplasm:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.73 C11orf80 CDKN1C CGA CGB3 CGB5 CSH1
2 reproductive system MP:0005389 9.47 C11orf80 CDKN1C CGA CGB3 CGB5 CSH1

Drugs & Therapeutics for Gestational Trophoblastic Neoplasm

Drugs for Gestational Trophoblastic Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amifostine Approved, Investigational Phase 3 20537-88-6 2141
2
Levoleucovorin Approved, Experimental, Investigational Phase 2, Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
3
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 4112 126941
4
Nitroglycerin Approved, Investigational Phase 2, Phase 3 55-63-0 4510
5
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
6
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
10
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
11
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
12
Letrozole Approved, Investigational Phase 2, Phase 3 112809-51-5 3902
13
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
14
Ethinylestradiol Approved Phase 3 57-63-6 5991
15
Polyestradiol phosphate Approved Phase 3 28014-46-2
16
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
17
Moxifloxacin Approved, Investigational Phase 3 186826-86-8, 354812-41-2, 151096-09-2 152946
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 59-30-3 6037
19 Vitamins Phase 2, Phase 3
20 Trace Elements Phase 2, Phase 3
21 Micronutrients Phase 2, Phase 3
22 Antidotes Phase 2, Phase 3
23 Calcium, Dietary Phase 2, Phase 3
24 Liver Extracts Phase 3
25 Hematinics Phase 3
26 Chrysarobin Phase 3
27 Cactinomycin Phase 3
28 Protective Agents Phase 3
29 Radiation-Protective Agents Phase 3
30 Folic Acid Antagonists Phase 2, Phase 3
31 Antirheumatic Agents Phase 3
32 Folate Phase 2, Phase 3
33 Vitamin B9 Phase 2, Phase 3
34 Antimetabolites Phase 3
35 Vitamin B Complex Phase 2, Phase 3
36 Immunosuppressive Agents Phase 3
37 Dermatologic Agents Phase 3
38 Immunologic Factors Phase 3
39 Antibiotics, Antitubercular Phase 3
40
Etoposide phosphate Phase 3 16760419
41 Alkylating Agents Phase 3
42 Albumin-Bound Paclitaxel Phase 3
43 Antineoplastic Agents, Alkylating Phase 3
44 Antimitotic Agents Phase 3
45 Tubulin Modulators Phase 3
46 Estrogens Phase 2, Phase 3
47 Estrogen Receptor Antagonists Phase 2, Phase 3
48 Estrogen Antagonists Phase 2, Phase 3
49 Hormones Phase 2, Phase 3
50 Hormone Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Unknown status NCT01630954 Phase 4
2 A Multicenter, Prospective, Randomized Trial of Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia Unknown status NCT01823315 Phase 3 MTX 1;MTX 2
3 Comparison Between Rescue Regimen and High Dose Methotrexate in the Managment of Presistent Gestational Trophoplastic Neoplasia :( A Randomized Controlled Trial ) Unknown status NCT03280979 Phase 2, Phase 3 rescue regimen;high dose methotrxate
4 Primary Surgery Plus Single Course Methotrexate Versus Primary Methotrexate for Treatment of Gestational Trophoblastic Neoplasms in Low Risk Cases Above 40y: a Randomized Controled Trial Unknown status NCT02606539 Phase 2, Phase 3 Methotrexate plus folinic acid alone
5 The Efficacy of Methotrexate for the Prevention of Postmolar Gestational Trophoblastic Disease Among Patients With High-Risk Hydatidiform Mole Completed NCT01984099 Phase 3 Methotrexate;Vitamin B Complex
6 A Randomized Phase III Trial of Weekly Parenteral Methotrexate Versus "Pulsed" Dactinomycin as Primary Management for Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003702 Phase 3 Methotrexate
7 A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia Completed NCT01535053 Phase 3 Leucovorin Calcium;Methotrexate
8 A Randomized Phase III Trial of Amifostine vs. No Treatment for Platinum Induced Peripheral Neuropathy Completed NCT00058071 Phase 3 amifostine trihydrate
9 Impact of Second Uterine Evacuation in Women With Non-metastatic, Low-risk Gestational Trophoblastic Neoplasia: A Phase III Trial Recruiting NCT04756713 Phase 3 Chemotherapy
10 A Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia Recruiting NCT03703271 Phase 3 Methotrexate
11 A Prospective Randomized Multicenter Clinical Control Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor Recruiting NCT02639650 Phase 3 Etoposide;actinomycin D;methotrexate;vincristine;cyclophosphamide;Paclitaxel;Cisplatin;Carboplatin
12 Women's Hospital, Zhejiang University School of Medicine Recruiting NCT03885388 Phase 2, Phase 3 MTX;MTX+ACTD
13 The Prophylactic Role of Aromatase Inhibitor Letrozole in Decreasing the Incidence of Gestational Trophoblastic Neoplasia in Patients With Complete Hydatidiform Mole Active, not recruiting NCT05203562 Phase 2, Phase 3 Letrozole tablets
14 Randomized, Double Blinded, Placebo-Controlled Trial of Antibacterial Prophylaxis for the Prevention of Bacterial Infections in the Post-Engraftment Phase After Allogeneic Hematopoeitic Stem Cell Transplantation Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
15 A Phase II Study to Determine the Response to Second Curettage as Initial Management for Persistent Low Risk, Non-metastatic Gestational Trophoblastic Neoplasia Completed NCT00521118 Phase 2
16 A Phase II Trial of Pemetrexed (Alimta) in the Treatment of Recurrent or Persistent Low Risk Gestational Trophoblastic Tumor Completed NCT00190918 Phase 2 Pemetrexed
17 Camrelizumab Combined With Apatinib for Recurrent Resistant Gestational Trophoblastic Neoplasia: a Phase 2, Single-arm, Prospective Study Completed NCT04047017 Phase 2 Apatinib;Camrelizumab
18 Pulse Actinomycin-D as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Neoplasia Completed NCT00003688 Phase 2
19 A Phase II Trial of Avelumab in Chemo-resistant Gestational Trophoblastic Neoplasias (GTN) Completed NCT03135769 Phase 2 Avelumab administration at 10mg/kg
20 Psychosexual Intervention for Gynecologic and Breast Cancer Patients Completed NCT01764802 Phase 2
21 A Phase II Study to Evaluate Low-Dose Alemtuzumab as a Glucocorticoid-Sparing Agent for Initial Systemic Treatment of Acute Graft-Versus-Host Disease Completed NCT00410657 Phase 2 methylprednisolone;prednisone
22 Prevention of DMSO-Related Nausea and Vomiting by Prophylactic Administration of Ondansetron for Patients Receiving Autologous Cryopreserved Peripheral Blood Stem Cells Completed NCT00795769 Phase 2 ondansetron
23 Phase II Clinical Trial Incorporating Alemtuzumab (Campath-1H) in Combination With FK506 and Methylprednisolone for Treatment of Severe Acute Graft vs Host Disease Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
24 Combination of Interleukin 11 (Neumega) With G-CSF to Mobilize Autologous Peripheral Blood Stem Cells (PBSC) Completed NCT00004157 Phase 2
25 Cytokine-Based Immunotherapy Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation Completed NCT00003408 Phase 2
26 A Phase I-II Safety, Tolerability And Pharmacokinetic Study Of Ravuconazole For Prophylaxis Of Invasive Fungal Infections In Patients Undergoing Non-Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT00064311 Phase 1, Phase 2 ravuconazole
27 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
28 Donor Lymphocyte Infusion (DLI) as Adoptive Immunotherapy for Relapse Malignancies After Allogeneic Hematopoietic Transplantation Completed NCT00003887 Phase 2
29 Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia: a Cohort, Open-label, Phase 2 Trial Recruiting NCT05139095 Phase 2 Camrelizumab plus apatinib CohortA;Camrelizumab plus apatinib Cohort B
30 Phase II Single-arm Clinical Study of PD-1 Antibody and Bevacizumab in the Treatment of Relapsed or Refractory High-risk Gestational Trophoblasitc Neoplasia After Second-line or Above Combined Chemotherapy Recruiting NCT04812002 Phase 2 PD-1 inhibitor, bevacizumab
31 TROPHAMET, a Phase I/II Trial of Avelumab and METhotrexate in Low-risk Gestational TROPHoblastic Neoplasias as First Line Treatment Recruiting NCT04396223 Phase 1, Phase 2 Avelumab Injection;Methotrexate 1 GM Injection
32 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
33 A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia Not yet recruiting NCT05635344 Phase 2 Pembrolizumab
34 Phase 2 Single Agent Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia (GTN) Not yet recruiting NCT05405192 Phase 2 Dostarlimab
35 Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab Not yet recruiting NCT04303884 Phase 2 Pembrolizumab Injection [Keytruda]
36 A Phase 2A Study of TRC105 (With Option to Add Bevacizumab) in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Terminated NCT02664961 Phase 2 TRC105;Bevacizumab
37 A Phase II Trial of Pemetrexed (ALIMTA®, LY231514, IND #40061) as Salvage Therapy for Failed Low Risk Gestational Trophoblastic Tumor Terminated NCT00096187 Phase 2 pemetrexed disodium
38 Deferasirox Treatment and Labile Plasma Iron in Iron Overloaded Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation Terminated NCT01159067 Phase 2 deferasirox
39 A Phase I Trial of Recombinant Human Interleukin-12 After High-Dose Therapy and Autologous Hematopoietic Stem Cell Support Completed NCT00003107 Phase 1
40 Prolonged Infusion Compared to Standard Infusion Cefepime as Empiric Treatment of Febrile Neutropenia: A Pilot Study Completed NCT01484015 Phase 1 cefepime hydrochloride
41 Detection of Minimal Amount of Human Chorionic Gonadotropin by Interferometry in Gestational Trophoblastic Disease Unknown status NCT00166790 chemotherapy agents
42 A Global Assessment of Medical, Emotional and Reproductive Concerns in Gestational Trophoblastic Disease Survivors Completed NCT00706875
43 Randomized-Controlled, Pilot Study of the Effects of a Brief, Scripted Sexual Health Intervention on Sexual Function for Women With Gynecologic Cancer Completed NCT02096783
44 A Pilot Study to Evaluate the Potential Efficacy of Lithium Carbonate for Stimulation of Intestinal Recovery In Patients With Acute Graft-versus-host Disease (GVHD) Completed NCT00408681 lithium carbonate
45 Pilot Study Evaluating Aprepitant (MK-869) for Prevention of Nausea & Vomiting Secondary to High Dose Cyclophosphamide Administered to Patients Underging Undergoing Peripheral Hematopoietic Progenitor Cell Mobilization Prior to Autologous Transplantation Completed NCT00293384 Aprepitant;Cyclophosphamide;Dexamethasone;Granisetron hydrochloride
46 Emotional Needs of Caregivers and Patient/Spouse Couples During Hematopoietic Stem Cell Transplantation (HSCT) Completed NCT00082654
47 Tissue Bank for Studies Related to Graft-Versus-Host Disease (GVHD) Completed NCT00900406
48 Acquisition of Human Gynecologic Specimens to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer Completed NCT00897442
49 A Biobehavioral Intervention for Patients With Gynecologic or Breast Cancer Recurrence Completed NCT01764789
50 The French National Reference Centre of Gestational Trophoblastic Disease Recruiting NCT02892877

Search NIH Clinical Center for Gestational Trophoblastic Neoplasm

Cochrane evidence based reviews: hydatidiform mole

Genetic Tests for Gestational Trophoblastic Neoplasm

Anatomical Context for Gestational Trophoblastic Neoplasm

Organs/tissues related to Gestational Trophoblastic Neoplasm:

MalaCards : Placenta, Lung, T Cells, Breast, Uterus, Liver, Thyroid

Publications for Gestational Trophoblastic Neoplasm

Articles related to Gestational Trophoblastic Neoplasm:

(show top 50) (show all 5967)
# Title Authors PMID Year
1
NLRP7 inter-domain interactions: the NACHT-associated domain is the physical mediator for oligomeric assembly. 62 5
25082979 2014
2
Mutations in NLRP7 and KHDC3L confer a complete hydatidiform mole phenotype on digynic triploid conceptions. 62 5
23125094 2013
3
Histopathological features of biparental complete hydatidiform moles in women with NLRP7 mutations. 62 5
23201303 2013
4
Mutations in NLRP7 are associated with diploid biparental hydatidiform moles, but not androgenetic complete moles. 62 5
22315435 2012
5
NLRP7 in the spectrum of reproductive wastage: rare non-synonymous variants confer genetic susceptibility to recurrent reproductive wastage. 62 5
21659348 2011
6
Identification of 13 novel NLRP7 mutations in 20 families with recurrent hydatidiform mole; missense mutations cluster in the leucine-rich region. 62 5
19246479 2009
7
NLRP7 mutations in women with diploid androgenetic and triploid moles: a proposed mechanism for mole formation. 62 5
19066229 2009
8
A recurrent intragenic genomic duplication, other novel mutations in NLRP7 and imprinting defects in recurrent biparental hydatidiform moles. 62 5
18039680 2008
9
Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. 62 5
16462743 2006
10
Analysis of the chromosomal region 19q13.4 in two Chinese families with recurrent hydatidiform mole. 62 5
16239310 2006
11
Familial recurrent molar pregnancy: a case report. 62 5
14756744 2004
12
The maternally transcribed gene p57(KIP2) (CDNK1C) is abnormally expressed in both androgenetic and biparental complete hydatidiform moles. 62 5
12471053 2002
13
Recurrent molar pregnancy: report of a case with seven consecutive hydatidiform moles. 62 5
11598368 2001
14
Mole maker phenotype: possible narrowing of the candidate region. 62 5
10951527 2000
15
Genetic mapping of a maternal locus responsible for familial hydatidiform moles. 62 5
10072436 1999
16
Hydatidiform mole and fetus with normal karyotype: support of a separate entity. 62 5
2030859 1991
17
The p.L750V mutation in the NLRP7 gene is frequent in Mexican patients with recurrent molar pregnancies and is not associated with recurrent pregnancy loss. 5
23354651 2013
18
Mosaic moles and non-familial biparental moles are not caused by mutations in NLRP7, NLRP2 or C6orf221. 5
22909446 2012
19
An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages. 5
22361007 2012
20
A strong founder effect for two NLRP7 mutations in the Indian population: an intriguing observation. 5
19650864 2009
21
Homozygous NLRP7 mutations in a Moroccan woman with recurrent reproductive failure. 5
19054016 2009
22
Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease. 53 62
20116088 2010
23
An aggressive course of de novo ulcerative colitis after renal transplantation: colonic adenocarcinoma with choriocarcinomatous differentiation. 53 62
19927772 2009
24
Gestational trophoblastic tumor with liver metastasis after misoprostol abortion. 53 62
18762963 2009
25
The use of plasmapheresis for rapid hormonal control in severe hyperthyroidism caused by a partial molar pregnancy. 53 62
18726107 2009
26
External validation of serum hCG cutoff levels for prediction of resistance to single-agent chemotherapy in patients with persistent trophoblastic disease. 53 62
19293810 2009
27
[Persistent low levels of human chorionic gonadotropin in the serum: investigation and management]. 53 62
19627038 2009
28
[Trophoblastic diseases]. 53 62
19009808 2008
29
Practical issues in the management of low-risk gestational trophoblast tumors. 53 62
19004403 2008
30
Trophoblastic disease: Analytical problems associated with HCG assay. 53 62
18852174 2008
31
Blood test for placental site trophoblastic tumor and nontrophoblastic malignancy for evaluating patients with low positive human chorionic gonadotropin results. 53 62
18720919 2008
32
Early identification of persistent trophoblastic disease with serum hCG concentration ratios. 53 62
17511799 2008
33
Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands. 53 62
17462723 2007
34
A model for the behavior of beta-hCG after evacuation of hydatidiform moles. 53 62
17395254 2007
35
Postevacuation hCG levels and risk of gestational trophoblastic neoplasia among women with partial molar pregnancies. 53 62
17165432 2006
36
Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy. 53 62
16964426 2006
37
The need for an hCG assay that appropriately detects trophoblastic disease and other hCG-producing cancers. 53 62
17086808 2006
38
Predictors of low risk of persistent trophoblastic disease in molar pregnancies. 53 62
16648403 2006
39
[Syndrome of persistent low levels of human chorionic gonadotrophin (hCG)]. 53 62
16649415 2006
40
Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease. 53 62
16711513 2006
41
Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios. 53 62
16189178 2005
42
Postevacuation hCG levels and risk of gestational trophoblastic neoplasia in women with complete molar pregnancy. 53 62
16135585 2005
43
[Diagnostic significance of tumor markers for gynecologic malignancies]. 53 62
15791829 2005
44
The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. 53 62
15581942 2004
45
Low risk of relapse after achieving undetectable HCG levels in women with complete molar pregnancy. 53 62
15339768 2004
46
Immunohistochemical characterization of p57Kip2 expression in tetraploid hydropic placentas. 53 62
15270611 2004
47
Management of persistent, unexplained, low-level human chorionic gonadotropin elevation: a report of 5 cases. 53 62
15305828 2004
48
The human chorionic gonadotropin molecule from patients with trophoblastic diseases has a high thyrotropic activity but is less active in the ovary. 53 62
15346663 2004
49
Abnormal biantennary sugar chains are expressed in human chorionic gonadotropin produced in the choriocarcinoma cell line, JEG-3. 53 62
15316280 2004
50
[Luteinized cystic ovarian hyperplasia during a normal pregnancy]. 53 62
12843886 2003

Variations for Gestational Trophoblastic Neoplasm

ClinVar genetic disease variations for Gestational Trophoblastic Neoplasm:

5 (show top 50) (show all 219)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2077C>T (p.Arg693Trp) SNV Pathogenic
1586 rs104895506 GRCh37: 19:55449464-55449464
GRCh38: 19:54938096-54938096
2 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2078G>C (p.Arg693Pro) SNV Pathogenic
1587 rs104895502 GRCh37: 19:55449463-55449463
GRCh38: 19:54938095-54938095
3 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2738A>G (p.Asn913Ser) SNV Pathogenic
1588 rs104895503 GRCh37: 19:55441939-55441939
GRCh38: 19:54930571-54930571
4 NLRP7 NM_001127255.2(NLRP7):c.1294C>T (p.Arg432Ter) SNV Pathogenic
1589 rs104895530 GRCh37: 19:55450893-55450893
GRCh38: 19:54939525-54939525
5 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2078G>A (p.Arg693Gln) SNV Pathogenic
1591 rs104895502 GRCh37: 19:55449463-55449463
GRCh38: 19:54938095-54938095
6 NLRP7 NM_001127255.2(NLRP7):c.1193T>G (p.Leu398Arg) SNV Pathogenic
1592 rs104895548 GRCh37: 19:55450994-55450994
GRCh38: 19:54939626-54939626
7 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2030delT (p.Leu677Profs) DEL Pathogenic
41407 rs104895554 GRCh37: 19:55449511-55449511
GRCh38: 19:54938143-54938143
8 NLRP7 NM_001127255.2(NLRP7):c.939_952dup (p.Tyr318Cysfs) DUP Pathogenic
97807 rs104895547 GRCh37: 19:55451234-55451235
GRCh38: 19:54939866-54939867
9 NLRP7 NM_001127255.2(NLRP7):c.336dup (p.Glu113Glyfs) DUP Pathogenic
97796 rs104895553 GRCh37: 19:55452313-55452314
GRCh38: 19:54940945-54940946
10 NLRP7 NM_001127255.1(NLRP7):c.352+1G>A SNV Pathogenic
1584 rs104895504 GRCh37: 19:55452298-55452298
GRCh38: 19:54940930-54940930
11 NLRP7, NCR1 NM_001127255.1(NLRP7):c.2471+1G>A SNV Pathogenic
1585 rs104895505 GRCh37: 19:55445856-55445856
GRCh38: 19:54934488-54934488
12 NLRP7 NM_001127255.2(NLRP7):c.1951C>T (p.Pro651Ser) SNV Pathogenic
1593 rs104895549 GRCh37: 19:55449590-55449590
GRCh38: 19:54938222-54938222
13 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2248C>G (p.Leu750Val) SNV Pathogenic
97750 rs104895512 GRCh37: 19:55447681-55447681
GRCh38: 19:54936313-54936313
14 NLRP7 NM_001127255.2(NLRP7):c.1857_1858delAC (p.Lys619Asnfs) DEL Pathogenic
812700 rs2069070395 GRCh37: 19:55450329-55450330
GRCh38: 19:54938961-54938962
15 NLRP7 NM_001127255.2(NLRP7):c.1224_1232delGCGGGGCGCinsT (p.Arg409Alafs) INDEL Pathogenic
997708 rs2069116238 GRCh37: 19:55450955-55450963
GRCh38: 19:54939587-54939595
16 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2647C>T (p.Gln883Ter) SNV Likely Pathogenic
1324813 GRCh37: 19:55442030-55442030
GRCh38: 19:54930662-54930662
17 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2011_2012delTT (p.Phe671Glnfs) DEL Likely Pathogenic
1324812 GRCh37: 19:55449529-55449530
GRCh38: 19:54938161-54938162
18 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2320_2321insT (p.Thr774Ilefs) INSERT Likely Pathogenic
830330 rs2068825510 GRCh37: 19:55446007-55446008
GRCh38: 19:54934639-54934640
19 NLRP7 NM_001127255.2(NLRP7):c.531C>T (p.His177=) SNV Conflicting Interpretations Of Pathogenicity
330181 rs746150420 GRCh37: 19:55451656-55451656
GRCh38: 19:54940288-54940288
20 NLRP7 NM_001127255.2(NLRP7):c.1718G>A (p.Gly573Asp) SNV Uncertain Significance
330165 rs149696586 GRCh37: 19:55450469-55450469
GRCh38: 19:54939101-54939101
21 NLRP7, NCR1 NM_001127255.2(NLRP7):c.*5C>T SNV Uncertain Significance
330154 rs115724298 GRCh37: 19:55435103-55435103
GRCh38: 19:54923735-54923735
22 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2548C>T (p.His850Tyr) SNV Uncertain Significance
330159 rs886054632 GRCh37: 19:55445031-55445031
GRCh38: 19:54933663-54933663
23 NLRP7 NM_001127255.2(NLRP7):c.9G>A (p.Ser3=) SNV Uncertain Significance
127264 rs199475821 GRCh37: 19:55453071-55453071
GRCh38: 19:54941703-54941703
24 NLRP7 NM_001127255.2(NLRP7):c.1168C>T (p.Arg390Cys) SNV Uncertain Significance
330171 rs543019983 GRCh37: 19:55451019-55451019
GRCh38: 19:54939651-54939651
25 NLRP7 NM_001127255.2(NLRP7):c.1257C>G (p.Ala419=) SNV Uncertain Significance
330170 rs151120858 GRCh37: 19:55450930-55450930
GRCh38: 19:54939562-54939562
26 NLRP7 NM_001127255.2(NLRP7):c.66A>G (p.Leu22=) SNV Uncertain Significance
330186 rs149175257 GRCh37: 19:55453014-55453014
GRCh38: 19:54941646-54941646
27 NLRP7 NM_001127255.2(NLRP7):c.749T>G (p.Phe250Cys) SNV Uncertain Significance
330178 rs78096121 GRCh37: 19:55451438-55451438
GRCh38: 19:54940070-54940070
28 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2373G>A (p.Leu791=) SNV Uncertain Significance
330161 rs768473188 GRCh37: 19:55445955-55445955
GRCh38: 19:54934587-54934587
29 NLRP7 NM_001127255.2(NLRP7):c.1113G>A (p.Thr371=) SNV Uncertain Significance
330173 rs531055840 GRCh37: 19:55451074-55451074
GRCh38: 19:54939706-54939706
30 NLRP7 NM_001127255.2(NLRP7):c.977A>T (p.Glu326Val) SNV Uncertain Significance
330175 rs146193856 GRCh37: 19:55451210-55451210
GRCh38: 19:54939842-54939842
31 NLRP7 NM_001127255.2(NLRP7):c.1488C>T (p.Asp496=) SNV Uncertain Significance
330168 rs775944680 GRCh37: 19:55450699-55450699
GRCh38: 19:54939331-54939331
32 KIR3DL1, NLRP7 NM_001127255.2(NLRP7):c.1137G>C (p.Lys379Asn) SNV Uncertain Significance
97715 rs10418277 GRCh37: 19:55451050-55451050
GRCh38: 19:54939682-54939682
33 NLRP7 NM_001127255.2(NLRP7):c.1138G>C (p.Gly380Arg) SNV Uncertain Significance
97716 rs104895557 GRCh37: 19:55451049-55451049
GRCh38: 19:54939681-54939681
34 NLRP7 NM_001127255.2(NLRP7):c.1196G>A (p.Cys399Tyr) SNV Uncertain Significance
97717 rs104895510 GRCh37: 19:55450991-55450991
GRCh38: 19:54939623-54939623
35 NLRP7 NM_001127255.2(NLRP7):c.1302C>T (p.Asp434=) SNV Uncertain Significance
97718 rs104895545 GRCh37: 19:55450885-55450885
GRCh38: 19:54939517-54939517
36 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2094C>T (p.His698=) SNV Uncertain Significance
97734 rs104895524 GRCh37: 19:55449447-55449447
GRCh38: 19:54938079-54938079
37 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2095G>A (p.Val699Ile) SNV Uncertain Significance
97735 rs77072552 GRCh37: 19:55449446-55449446
GRCh38: 19:54938078-54938078
38 NLRP7 NM_001127255.2(NLRP7):c.555C>T (p.Thr185=) SNV Uncertain Significance
330180 rs754428027 GRCh37: 19:55451632-55451632
GRCh38: 19:54940264-54940264
39 NLRP7 NM_001127255.2(NLRP7):c.835G>T (p.Val279Leu) SNV Uncertain Significance
330177 rs144378653 GRCh37: 19:55451352-55451352
GRCh38: 19:54939984-54939984
40 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2788A>T (p.Asn930Tyr) SNV Uncertain Significance
290323 rs201379032 GRCh37: 19:55441889-55441889
GRCh38: 19:54930521-54930521
41 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2402T>C (p.Leu801Pro) SNV Uncertain Significance
834074 rs2068817265 GRCh37: 19:55445926-55445926
GRCh38: 19:54934558-54934558
42 NLRP7, NCR1 NM_001127255.2(NLRP7):c.*44G>A SNV Uncertain Significance
892762 rs201167539 GRCh37: 19:55435064-55435064
GRCh38: 19:54923696-54923696
43 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2226C>T (p.Ile742=) SNV Uncertain Significance
892800 rs571211521 GRCh37: 19:55447703-55447703
GRCh38: 19:54936335-54936335
44 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2204A>G (p.His735Arg) SNV Uncertain Significance
892801 rs2068925515 GRCh37: 19:55447725-55447725
GRCh38: 19:54936357-54936357
45 NLRP7, NCR1 NM_001127255.2(NLRP7):c.2154C>T (p.Thr718=) SNV Uncertain Significance
892802 rs372489727 GRCh37: 19:55447775-55447775
GRCh38: 19:54936407-54936407
46 NLRP7 NM_001127255.2(NLRP7):c.1823C>T (p.Ser608Phe) SNV Uncertain Significance
127260 rs199475830 GRCh37: 19:55450364-55450364
GRCh38: 19:54938996-54938996
47 NLRP7 NM_001127255.2(NLRP7):c.1149G>A (p.Pro383=) SNV Uncertain Significance
892830 rs752268912 GRCh37: 19:55451038-55451038
GRCh38: 19:54939670-54939670
48 NLRP7 NM_001127255.2(NLRP7):c.1111A>G (p.Thr371Ala) SNV Uncertain Significance
892831 rs748263335 GRCh37: 19:55451076-55451076
GRCh38: 19:54939708-54939708
49 NLRP7 NM_001127255.2(NLRP7):c.1104T>G (p.Ile368Met) SNV Uncertain Significance
892832 rs1654636 GRCh37: 19:55451083-55451083
GRCh38: 19:54939715-54939715
50 NLRP7 NM_001127255.2(NLRP7):c.361G>A (p.Glu121Lys) SNV Uncertain Significance
892857 rs2069175044 GRCh37: 19:55451826-55451826
GRCh38: 19:54940458-54940458

Expression for Gestational Trophoblastic Neoplasm

Search GEO for disease gene expression data for Gestational Trophoblastic Neoplasm.

GO Terms for Gestational Trophoblastic Neoplasm

Cellular components related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 subcortical maternal complex GO:0106333 9.26 NLRP5 KHDC3L
2 pituitary gonadotropin complex GO:0061696 9.02 CGB5 CGB3 CGA

Biological processes related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of embryonic development GO:0040019 9.62 NLRP5 KHDC3L
2 growth hormone receptor signaling pathway GO:0060396 9.56 CSH2 CSH1
3 positive regulation of growth GO:0045927 9.46 CSH2 CSH1
4 hormone-mediated signaling pathway GO:0009755 9.35 CGB5 CGB3 CGA
5 establishment of organelle localization GO:0051656 8.92 NLRP5 KHDC3L

Molecular functions related to Gestational Trophoblastic Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.36 INHA CSH2 CSH1 CGB5 CGB3 CGA
2 growth hormone receptor binding GO:0005131 9.26 CSH2 CSH1

Sources for Gestational Trophoblastic Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....